on NOVACYT (EPA:ALNOV)
Novacyt launches LightBench® Discover
Novacyt SA, a leader in molecular diagnostics, announces the launch of LightBench® Discover. This 3-in-1 instrument is designed for genomics research laboratories using long-read sequencing. The development benefited from a collaboration with PacBio® and the involvement of Yourgene Health, a PacBio® partner, since November 2023.
The LightBench® Discover replaces multiple instruments by combining large DNA fragment analysis, size selection, and fluorometric quantification. This integrated tool reduces costs and simplifies workflows. It is specifically designed for use with the PacBio Revio® or Vega™ systems.
A technical note, available on the Novacyt and PacBio® websites, presents the instrument's performance. Lyn Rees, Managing Director, highlights the benefits of LightBench® Discover in terms of efficiency and quality control.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all NOVACYT news